Add the specialty areas of your choice to tailor to your professional interests.
Save & Create free account
No thanks, just apply selection
I already have an account. Login

User login

We offer our registered users tailored information, free online courses and exclusive content.

Can't find your password?
Reset it here.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Brian Tomlinson

Brian Tomlinson
Specialist in Internal Medicine & Clinical Pharmacology
Department of Medicine and Therapeutics
Adjunct Professor
The Chinese University of Hong Kong
Hong Kong, China

Brian Tomlinson BSc (Lond), MBBS (Lond), MD (Lond), FRCP (Lond), FRCP (Edin), FRCP (Glasg), FHKAM (Medicine),FHKCP, FACP, FCP was formerly Chair Professor in the Department of Medicine and Therapeutics and Head of the Division of Clinical Pharmacology at the Chinese University of Hong Kong and honorary Consultant Physician at the Prince of Wales Hospital, Hong Kong. He trained in internal medicine and Clinical Pharmacology at the Middlesex Hospital Medical School and University College Hospital, London and received his MD from the University of London.

His clinical and research interests include the clinical pharmacology, toxicology and pharmacogenetics of drugs, particularly in the cardiovascular field, and the pathogenesis and treatment of hyperlipidaemia, hypertension, the metabolic syndrome and diabetes. He has trained over 30 postgraduate students and is an author of over 350 publications and over 500 conference abstracts and has given numerous invited lectures. He is a reviewer for many journals and serves on several Editorial Boards and is President of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases and Secretary General of the Pacific Rim Association for Clinical Pharmacogenetics.

Disclosure of faculty relationships

Brian Tomlinson declared receipt of grants from Amgen, Biogen, GlaxoSmithKline, Merck Serono, Merck Sharp and Dohme; receipt of honoraria or consultation fees from Boehringer-Ingelheim, Merck Serono and Ranbaxy; to be member of the advisory boards of Astra Zeneca, Genzyme and Merck Serono; participation in the speakers’ bureau of Boehringer-Ingelheim, Merck Serono and Ranbaxy.

EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of EXCEMED. All presentations solely represent the independent views of the presenters/authors.